CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I
Palabras clave :
Substrate reduction therapy
Mouse model
Vivo
Disease
System
Target
Replacement
Deficiency
Expression
Mutations
Fecha de publicación :
2018
Nota:
This is an open access article distributed under the Creative Commons: Atribution License (cc BY)
Cita:
Zabaleta-Lasarte, N. (Nerea); Barberia, M.; Martin-Higueras, C.; et al. "CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I". Nature communications. 9, 2018, 5454
Aparece en las colecciones:
Estadísticas e impacto
0 citas en
0 citas en
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.